Association of apolipoprotein Cs with new-onset type 2 diabetes mellitus: findings from the Chinese multi-provincial cohort study

Jianfeng Chen, Dong Zhao, Jing Liu, Miao Wang, Jiayi Sun, Jun Liu, Yan Li, Qiuju Deng, Yue Qi

ABSTRACT

Objectives Apolipoprotein Cs (apoCs), especially apoC-II and apoC-III, as the components of triglyceride-rich lipoproteins, play a key role in the pathophysiology of diabetes. However, prospective studies examining direct associations between apoCs and diabetes are not reproducible. The aim of this study was to evaluate the impact of apoCs on the risk of developing diabetes in a middle-aged population, and to explore possible mediators responsible for the relationship between apoCs and diabetes.

Design Prospective cohort study.

Setting Community-based study carried out in Beijing.

Methods ApoCs were measured in 1085 participants aged 45–74 years and free of type 2 diabetes mellitus (T2DM) at baseline from the Chinese Multi-Provincial Cohort Study-Beijing Project. Multivariate logistic regression was performed to examine the association of apoCs with a 5-year risk of new-onset T2DM. The impacts of triglycerides, insulin and high-sensitivity C reactive protein (hs-CRP) on the association between apoC-III and the risk of T2DM were explored by a mediation test.

Results During the 5 years of follow-up, 97 (8.9%) participants developed T2DM. ApoC-III was significantly associated with the risk of developing T2DM after multivariable adjustment (OR= 1.40; 95% CI 1.07 to 1.82). This association was mainly mediated by triglyceride levels with a significant indirect effect (OR 1.61; 95% CI 1.19 to 2.18), followed by hs-CRP and insulin.

Conclusions Our findings demonstrated that higher serum apoC-III was independently associated with increased 5-year risk of new-onset T2DM in the Chinese population, and triglyceride plays a crucial role in mediating this relationship. More attention should be paid to preventive strategies of T2DM targeting apoC-III.

INTRODUCTION

Diabetes is an important cause of morbidity and mortality, leading to heavy disease and economic burdens worldwide, especially in low-income and middle-income countries. In China, diabetes has reached epidemic proportions, with 11.6% of adults suffering from diabetes, accounting for an estimated 103 million adults, and about 24% of the global number of patients with diabetes, and China is among the countries with the highest diabetes prevalence in Asia and has the largest burden of diabetes worldwide. However, current preventive strategies primarily targeting glucose homeostasis have failed to mitigate the growing burden. Consequently, identifying novel risk factors related to diabetes is urgently needed to further the understanding of the aetiology and prevention of the disease.

More recent studies have found that lipid-related pathways are involved in regulating glucose homeostasis, suggesting the possibility of targeting lipid metabolism to prevent diabetes. Previous experimental studies suggested that apolipoprotein Cs (apoCs), especially apoC-II and apoC-III, as the components of triglyceride-rich lipoproteins, have a great influence on the lipolysis of triglycerides, as well as the ability to regulate insulin signalling, pancreatic beta-cell apoptosis and inflammation. These studies provided pathophysiological evidence for the
critical role of apoCs in the development of diabetes. To date, five prospective cohort studies\(^9\)–\(^{13}\) have reported on the association of apoC-II and apoC-III levels with diabetes risk, whereas the results were not often reproducible after controlling for triglycerides, leaving open the question of whether the apoCs are indeed associated with diabetes risk, and whether this association is dependent on triglycerides, as well as insulin and inflammation. Furthermore, most of the studies on apoCs and diabetes have been conducted in European or American populations, while the evidence from Asian populations is scarce.

Whether the levels of apoCs are indeed related to diabetes risk is critically important and relevant to diabetes prevention strategies. Therefore, the aim of this study was to evaluate the impact of serum apoCs levels on the risk of developing type 2 diabetes mellitus (T2DM) in a middle-aged community-based cohort of Chinese participants. In addition, this study was also aimed to investigate the mediation effects of triglyceride, insulin, and high-sensitivity C reactive protein (hs-CRP) on the association between apoCs and T2DM in light of the underlying physiological functions of apoCs involved in the development of diabetes.

METHODS

Study design and population

Study participants were recruited from the Chinese Multi-Provincial Cohort Study-Beijing Project, a population-based prospective cohort study. The details of study design and initial exclusion criteria have been described elsewhere.\(^{14}\) Briefly, 1392 non-diabetic participants aged 45–74 years completed questionnaires on demographic characteristics and measurements of traditional risk factors in 2002. All participants were followed up to identify any occurrence of cardiovascular diseases every 1–2 years from baseline and invited to a repeated examination to identify risk factors in 2007. After excluding participants for the following reasons: unavailable blood samples (n=134), death of causes other than T2DM (n=33), and loss to follow-ups (n=140), totally 1085 participants were enrolled for this study (online supplemental figure 1). Written informed consents were obtained from all participants.

Risk factor surveys

Demographic and clinical characteristics were collected via standardised questionnaires in all the surveys, including demographic characteristics, personal and family medical history, medical therapy, smoking status, and alcohol consumption.

Anthropometric measurements, including height and weight, and blood pressure, were obtained by trained physicians during physical examination. Body mass index (BMI) was calculated as weight in kilograms divided by height in metres squared. Blood pressure was calculated by averaging two consecutive recordings, measured at the right-side brachial artery with the participants in a sitting position using a mercury sphygmomanometer after resting for at least 5 min. Current smoking was defined as smoking one or more cigarettes per day for more than 3 months. Current drinking was defined as drinking at least once a month for more than 6 months. Overweight was defined as having a BMI of 25 kg/m\(^2\) or higher.\(^{15}\) Hypertension was defined as systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg and/or current antihypertensive treatment. Physical activity was defined as at least 150 min of moderate-intensity physical activity or 75 min of high-intensity physical activity (or equivalent combination of moderate-intensity and high-intensity physical activity) every week.

Laboratory measurements

Venous blood samples were collected for laboratory measurements after fasting for at least 8 hours. Total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, fasting blood glucose (FBG), and triglyceride were measured using fresh samples on the day of collection using the same method in all the surveys. Total cholesterol, FBG and triglyceride levels were tested by enzymatic methods (Human Diagnostics, Wiesbaden, Germany). Low-density lipoprotein cholesterol and high-density lipoprotein cholesterol levels were measured using a homogeneous method (Daichi, Tokyo, Japan). The remaining samples were stored at −80°C without repeated freeze-thaw cycles to minimise the degradation. Fasting insulin levels were determined by chemiluminescent immunoassay in 2008. Hs-CRP levels were determined using a particle-enhanced immunoturbidimetric method (DiaSys, Holzheim, Germany) in 2008. Baseline ApoCs levels were tested by immunoturbidimetric method (Sekisui Medical, Tokyo, Japan) in 2015. The coefficient of variation (CV) of apoC-II was 1.29% for low-range controls and 2.68% for high-range controls. The CV of apoC-III was 1.67% for low-range controls and 2.30% for high-range controls. Insulin resistance was estimated by homoeostasis model assessment of insulin resistance (HOMA-IR), which was calculated as the formulae: HOMA-IR=fasting insulin (μIU/mL) FBG (mmol/L)/22.5.\(^{16}\)

Case ascertainment

New-onset T2DM was determined if any of the following criteria were met: (1) previously diagnosed by a physician; (2) use of insulin or glucose-lowering medications during the past 2 weeks; (3) FBG ≥126 mg/dL; (4) death of T2DM during the follow-up visits that was established by the staff from collaborating centres and by regular searching of the death registration database of Beijing.\(^{17}\)

Sample size estimation

The risk estimates of apoC-III for T2DM reported in previous studies were 1.42–3.43. In our study, the rate of new-onset T2DM during follow-up was 8.94%. The SD of apoC-III was 4.23. \(R^2\) value for apoC-III with other T2DM risk factors was 0.15. The estimated maximum sample...
size was 74–922, assuming an alpha (probability of type I error) of 0.05 and a delta (admissible error) of 0.20. The actual sample size of 1085 enabled sufficient statistical power.

**Statistical analyses**

Continuous variables were expressed as means (±SD) in the case of normal distributions or as medians (IQR), and compared using unpaired Student’s t-test or Mann-Whitney U test, as appropriate. Categorical variables were expressed as numbers (percentages) and compared using the χ² test. Correlations between the levels of apoCs and other parameters were estimated using Spearman’s rank method after adjusting age and sex.

OR for new-onset T2DM associated with apoCs were calculated using the logistic regression model after adjustment for traditional metabolic risk factors and variables different between participants with and without new-onset T2DM, including age, sex, parental history for diabetes, overweight, physical activity, hypertension, current smoking, current drinking, lipid-lowering treatment, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, hs-CRP and FBG. Risk estimates were calculated for 1 SD increases in naturally log-transformed apoCs. Because participants did not undergo the oral glucose tolerance test at baseline, some participants with T2DM that was only identified by the oral glucose tolerance test were included, which was particularly the case among participants with impaired fasting glucose (IFG). Therefore, a sensitivity analysis was performed among participants without IFG (FBG >6.1 mmol/L) at baseline. Subgroup analyses were performed using baseline characteristics, including sex (male or female), age (<60 or ≥60 years), parental history of diabetes (no or yes), overweight (no or yes), current smoking (no or yes), current drinking (no or yes), physical activity (no or yes), hypertension (no or yes), triglyceride (<150 or ≥150 mg/dL),

### Table 1  Baseline characteristics of study participants

<table>
<thead>
<tr>
<th></th>
<th>Non-T2DM (n=988)</th>
<th>5-year new-onset T2DM (n=97)</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>59±8</td>
<td>60±8</td>
<td>0.234</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>552 (55.9)</td>
<td>45 (46.4)</td>
<td>0.073</td>
</tr>
<tr>
<td>Parental history of diabetes, n (%)</td>
<td>103 (10.4)</td>
<td>13 (13.4)</td>
<td>0.365</td>
</tr>
<tr>
<td>Body mass index, (kg/m²)</td>
<td>24.69±3.11</td>
<td>26.92±3.30</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Overweight, n (%)</td>
<td>439 (44.4)</td>
<td>68 (70.1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Systolic blood pressure (mm Hg)</td>
<td>128±18</td>
<td>138±17</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Diastolic blood pressure (mm Hg)</td>
<td>80±10</td>
<td>85±10</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>475 (48.1)</td>
<td>67 (69.1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Total cholesterol (mg/dL)</td>
<td>213.00 (189.00–237.00)</td>
<td>215.00 (193.50–249.50)</td>
<td>0.305</td>
</tr>
<tr>
<td>HDL cholesterol (mg/dL)</td>
<td>53.00 (45.00–62.00)</td>
<td>48.00 (41.50–53.50)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LDL cholesterol (mg/dL)</td>
<td>128.00 (108.25–148.00)</td>
<td>127.00 (100.50–152.50)</td>
<td>0.867</td>
</tr>
<tr>
<td>Triglycerides (mg/dL)</td>
<td>114.00 (82.00–164.00)</td>
<td>158.00 (106.50–232.50)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Fasting blood glucose (mg/dL)</td>
<td>83.00 (79.00–89.00)</td>
<td>95.00 (88.00–104.00)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Fasting insulin (uIU/mL)</td>
<td>6.1 (4.5–8.3)</td>
<td>8.2 (5.9–10.6)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>1.27 (0.91–1.76)</td>
<td>1.96 (1.30–2.58)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Hs-CRP (mg/L)</td>
<td>0.77 (0.36–1.67)</td>
<td>1.58 (0.74–3.73)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Current smoking, n (%)</td>
<td>110 (11.1)</td>
<td>13 (13.4)</td>
<td>0.501</td>
</tr>
<tr>
<td>Current drinking, n (%)</td>
<td>291 (29.5)</td>
<td>26 (26.8)</td>
<td>0.584</td>
</tr>
<tr>
<td>Physical activity, n (%)</td>
<td>263 (26.6)</td>
<td>33 (34.0)</td>
<td>0.122</td>
</tr>
<tr>
<td>Prevalent cardiovascular disease, n (%)</td>
<td>43 (4.4)</td>
<td>3 (3.1)</td>
<td>0.557</td>
</tr>
<tr>
<td>Lipid-lowering treatment, n (%)</td>
<td>102 (10.3)</td>
<td>18 (18.6)</td>
<td>0.014</td>
</tr>
<tr>
<td>Apolipoprotein C-II (mg/dL)</td>
<td>3.92 (2.69–5.43)</td>
<td>4.56 (3.06–6.72)</td>
<td>0.001</td>
</tr>
<tr>
<td>Apolipoprotein C-III (mg/dL)</td>
<td>9.80 (7.53–12.55)</td>
<td>11.74 (8.60–15.63)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Data are expressed as number (per cent) for categorical variables and as mean (SD) for continuous variables in case of normal distributions and median (IQR) otherwise.

*Unpaired Student’s t-test (when satisfying a normal distribution) or Mann-Whitney U test (when not satisfying a normal distribution) for quantitative variables and χ² test for qualitative variables.

HDL, high-density lipoprotein; HOMA-IR, homoeostasis model assessment of insulin resistance; hs-CRP, high-sensitivity C reactive protein; LDL, low-density lipoprotein; T2DM, type 2 diabetes mellitus; VLDL, very-low-density lipoprotein.
The dependent variable (Y); and triglycerides, insulin and was the independent variable (X); new-

between these variables:

three statistical equations illustrate the associations and apoC-


In mediation models, baseline apoC-

were explored by a mediation analysis

the association between apoC-

Z

subgroups were compared using a

statistic.18

factors were used as confounding variables. ORs between

regression model. Besides the grouping factors, other

100.8 mg/dL), HOMA-

lowering

(females) or

high-

density lipoprotein cholesterol (<40 (males)/50
(females) or ≥40 (males)/50 (females) mg/dL), lipid-

-9.5 or ≥9.5 mg/dL). The following

were potential intermediates between apoC-

and new-onset T2DM, which could dilute the relationship if erro-

neously adjusted for. Before conducting the mediation

analysis, these variables were compared between partici-

pants with and without new-onset T2DM. Sensitivity anal-

yses were conducted to further adjust for variables, which

were found to be significantly different between partici-

pants with and without new-onset T2DM.

Furthermore, to test whether missing data would intro-

duce potential bias, comparisons were performed between participants who were eligible for the final analyses and those who were unavailable for the re-examination (online supplemental table 1), revealing no significant differences with respect to lipid and glucose-related biomarkers.

Statistical analyses were performed using the R software (V.3.6.2, R Foundation for Statistical Computing) and IBM SPSS Statistics for Windows software, V.23.0. A p<0.05 on the two-sided test was considered statistically significant. Sample size estimation was calculated using the PASS software (V.11.0, NCSS).

Table 2  ORs of new-onset T2DM associated with the levels of apolipoprotein Cs

<table>
<thead>
<tr>
<th>Apolipoprotein C-II</th>
<th>All participants (n=1085)</th>
<th>Participants without IFG at baseline (n=1069)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR (95% CI) P value</td>
<td>OR (95% CI) P value</td>
</tr>
<tr>
<td>Unadjusted</td>
<td>1.54 (1.22 to 1.95) &lt;0.001</td>
<td>1.54 (1.20 to 1.98) &lt;0.001</td>
</tr>
<tr>
<td>Model 1</td>
<td>1.54 (1.22 to 1.95) &lt;0.001</td>
<td>1.56 (1.21 to 2.00) &lt;0.001</td>
</tr>
<tr>
<td>Model 2</td>
<td>1.34 (1.04 to 1.73) 0.023</td>
<td>1.30 (1.00 to 1.69) 0.054</td>
</tr>
<tr>
<td>Model 3</td>
<td>1.40 (1.08 to 1.81) 0.011</td>
<td>1.36 (1.04 to 1.79) 0.026</td>
</tr>
<tr>
<td>Model 4</td>
<td>1.25 (0.95 to 1.66) 0.117</td>
<td>1.21 (0.90 to 1.62) 0.203</td>
</tr>
<tr>
<td>Apolipoprotein C-III</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unadjusted</td>
<td>1.66 (1.33 to 2.08) &lt;0.001</td>
<td>1.65 (1.30 to 2.08) &lt;0.001</td>
</tr>
<tr>
<td>Model 1</td>
<td>1.71 (1.36 to 2.14) &lt;0.001</td>
<td>1.70 (1.34 to 2.16) &lt;0.001</td>
</tr>
<tr>
<td>Model 2</td>
<td>1.54 (1.21 to 1.96) 0.001</td>
<td>1.48 (1.15 to 1.91) 0.002</td>
</tr>
<tr>
<td>Model 3</td>
<td>1.59 (1.25 to 2.03) 0.001</td>
<td>1.54 (1.19 to 1.99) 0.001</td>
</tr>
<tr>
<td>Model 4</td>
<td>1.40 (1.07 to 1.82) 0.013</td>
<td>1.40 (1.06 to 1.84) 0.019</td>
</tr>
</tbody>
</table>

Model 1: adjusted for age (per 1 year), sex and parental history for diabetes.

Model 2: model 1+ overweight, hypertension, current smoking and current drinking, physical activity, lipid-lowering treatment, low-density lipoprotein cholesterol levels (per 1 mg/dL) and, high-density lipoprotein cholesterol (per 1 mg/dL).

Model 3: model 2+ naturally log-transformed high-sensitivity C reactive protein.

Model 4: model 3+ fasting blood glucose levels (per 1 mg/dL).

The ORs and corresponding CIs for 1 SD increases in naturally log-

transformed high-

density lipoprotein cholesterol and, high-

density lipopr
tin levels and, high-

sensitivity C reactive protein.

The impacts of triglycerides, insulin and hs-

CRP were the mediator variables (M). The following

equations illustrate the associations between these variables:

\[ Y = \alpha X + \epsilon_1 + \text{confounders.} \]

\[ M = \alpha X + \epsilon_2 + \text{confounders.} \]

\[ Y = \epsilon X + b M + \epsilon_3 + \text{confounders.} \]

The coefficient \( \epsilon \) of equation 1 is the total effect of X on Y; the coefficient \( \alpha \) of equation 2 is the effect of X on M; the coefficient \( b \) of equation 3 is the effect of M on Y after controlling for X; the coefficient \( \epsilon \) of equation 3 is the effect of X on Y after controlling for M. The indirect effect, indicating the effect of X on Y through M, was calculated as the product of coefficients \( ab \) and was estimated from 5000 bootstrap samples. The bootstrap method was used to test the significance of the indirect effect.\(^{19}\) The 10% change-in-estimate methods were used to select the main confounding factors, including age, sex and parental history for diabetes, which may be related to apoC-III level, T2DM and mediator variables, but are unlikely to be intermediate variables in the causal pathway of these relationships. Additional variables including overweight, hypertension, current smoking, current drinking, physical activity, lipid-lowering treatment, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol are potential intermediates between apoC-III and new-onset T2DM, which could dilute the relationship if erro-

neously adjusted for. Before conducting the mediation

analysis, these variables were compared between partici-

pants with and without new-onset T2DM. Sensitivity anal-

yses were conducted to further adjust for variables, which

were found to be significantly different between partici-

pants with and without new-onset T2DM.
RESULTS

Baseline characteristics

The 5-year rate of new-onset T2DM was 8.9% among the participants with a mean (±SD) age of 59 (±8) years old. The baseline characteristics of the study participants are shown in table 1. Those who developed new-onset T2DM during follow-up were more likely to have higher apoC-III, apoC-III, BMI, blood pressure, triglycerides, FBG, fasting insulin, HOMA-IR, and hs-CRP levels, as well as a higher proportion of participants using lipid-lowering treatment than those free of T2DM (table 1). Serum apoCs levels were correlated with lipids-related, glucose-related and inflammation-related parameters, especially with triglycerides (partial-r: 0.760 for apoC-II; 0.810 for apoC-III) (online supplemental table 2). These relations remained significant after excluding participants with lipid-lowering treatment.

Association of serum apoCs levels with the risk of new-onset T2DM

Table 2 displays the ORs and 95% CIs for the association between levels of serum apoCs and the risk of new-onset T2DM. After adjusting for age, sex, and parental history for diabetes, baseline apoC-II (OR 1.54; 95% CI 1.22 to 1.95) and apoC-III (OR 1.71; 95% CI 1.36 to 2.14) were both significantly and positively associated with the risk of new-onset T2DM. The OR values almost remained unchanged after adjustment for other traditional risk factors. However, only apoC-III was still significantly associated with the risk of developing T2DM after further adjustment for FBG. The OR and 95% CI for new-onset T2DM per one SD naturally log-transformed apoC-III was 1.40 (95% CI 1.07 to 1.82). After further excluding participants with IFG, the association between levels of serum apoCs and the risk of new-onset T2DM was similar (table 2). The relationship between apoC-III and T2DM risk was investigated among various subgroups stratified by cardiovascular risk factors. There were significant interactions between apoC-III and sex, and between apoC-III and triglycerides on new-onset T2DM (figure 1).

Mediation analysis for the impact of apoC-III on the risk of new-onset T2DM

In mediation analysis, the relationship of apoC-III to diabetes was shown to be mediated by triglyceride, insulin and hs-CRP (table 3). After adjusting for age, sex and parental history for diabetes, the total effect of apoC-III on the incidence of diabetes was 1.71 (95% CI 1.36 to 2.14). The indirect effect through triglyceride was 1.61 (95% CI 1.05 to 2.49), followed by hs-CRP and insulin, which had the indirect effect OR of 1.05 (95% CI 1.01 to 1.09), respectively. The results were similar for models before and after adjusting for additional variables significantly related to new-onset T2DM separately, including hypertension, overweight, lipid-lowering treatment and low levels of high-density lipoprotein cholesterol.

DISCUSSION

In this population-based cohort study, we carefully investigated the association between serum apoCs and the risk of developing diabetes. Our results showed that serum apoC-III was independently and positively associated with a 5-year risk of new-onset diabetes. Furthermore, the relationship between apoC-III and new-onset diabetes was mediated mainly by triglycerides.

The available literature on the association between apoC-III and T2DM risk is inconsistent, which may be due to differences in study populations, measurement of lipids, and multivariable-adjusted models. First, the mean age of participants in the Rotterdam Study was 73 (±7.5) years, and 51.4% of patients with coronary heart disease...
were included in the Danish Diet, Cancer and Health (DCH) study, which may bring about the higher risk of developing T2DM and strong relationship between apoC-III levels and new-onset T2DM. Second, the lipid and lipoproteins in the DCH study were measured in a non-fasting state and were subjected to more variability than fasting lipids. Finally, the relation between apoC-III and T2DM risk was different before and after adjusting for triglycerides in previous studies. Considering these issues, we investigated the association between apoC-III in the fasting state and new-onset T2DM with a generally healthy population with a mean age of 59 (range from 45 to 74) years and found that high apoC-III levels were associated with increased risk of new-onset T2DM by raising triglyceride levels, which is in line with previous studies that reported on the modified effect of triglycerides on the association between apoC-III and T2DM risk. Those studies reported that apoC-III was strongly correlated with triglycerides. The eliminated risk estimates of apoC-III with new-onset T2DM after adjustment for triglycerides reported in previous prospective studies suggested that triglycerides might modulate the relationship between apoC-III and T2DM. Using mediation analysis, we found a significant indirect effect on the relation between apoC-III and new-onset T2DM by triglycerides. Even after additional adjustment for baseline hs-CRP, blood glucose and other risk factors, the results were unchanged. The mediation of triglycerides may be explained by the ability of apoC-III to increase triglyceride levels by delaying and preventing the clearance of triglyceride-rich lipoproteins and promoting very-low-density lipoprotein assembly and secretion, which is the critical role of apoC-III in modulating glucose metabolism. Genetic studies of APOC3 loss-of-function variants, showing the association with lower levels of triglycerides and a reduced risk of cardiovascular disease, supported our findings. Furthermore, the EPIC-Norfolk Study reported that the robust association of elevated apoC-III levels and coronary artery disease risk could be likely explained by apoC-III’s association with triglyceride elevation, which indicated the proatherogenic effect of apoC-III might be mainly attributed to triglycerides. Although we showed strong correlations between apoC-III levels, T2DM risk and triglycerides, it should be stressed that this does not imply causality, and reported findings should be further confirmed by intervention studies. Currently, apoC-III targeted therapies are in the development stage, which the antisense oligonucleotide volanesorsen and AKCEA-APOCIII-LRx showing the most promise to date. This antisense oligonucleotide resulted in apoC-III reductions up to 93.1%, which translated to equally lowering of triglyceride (up to -77.8%). The strong impact of triglyceride on the association between apoC-III and T2DM we observed in the current study holds promise for the potential of these therapies to lower T2DM risk, which needs to be further tested by future trials.

Furthermore, apoC-III may also have an important role in carbohydrate homeostasis through other possible mechanisms beyond its involvement in triglyceride metabolism, such as proinflammatory effect and impairment insulin signalling. In line with these findings, our results demonstrated that high levels of apoC-III may also increase the risk of developing diabetes through insulin and hs-CRP. However, the indirect effects of insulin and inflammation are much lower than that of triglycerides, indicating the diabetogenic effect of apoC-III mainly via triglycerides. In addition, a significant interaction between sex and apoC-III on the developing diabetes was found, and apoC-III resulted as a better indicator of diabetes in males than in females. Consistent with our findings, genetic evidence suggested that APOC3 genetic variants were associated with disturbed glucose

Table 3  Mediation analyses of the relationship between apoC-III and new-onset T2DM through triglycerides, insulin and hs-CRP

<table>
<thead>
<tr>
<th>Mediators</th>
<th>Effect of apoC-III on diabetes*</th>
<th>OR (95% CI)</th>
<th>Model 1</th>
<th>Model 2</th>
<th>Model 3</th>
<th>Model 4</th>
<th>Model 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Triglyceride</td>
<td>Direct effect</td>
<td>1.00 (0.67 to 1.48)</td>
<td>1.01 (0.68 to 1.51)</td>
<td>1.07 (0.72 to 1.61)</td>
<td>0.99 (0.67 to 1.47)</td>
<td>1.04 (0.69 to 1.57)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Indirect effect</td>
<td>1.61 (1.19 to 2.18)</td>
<td>1.57 (1.16 to 2.14)</td>
<td>1.44 (1.08 to 1.94)</td>
<td>1.58 (1.19 to 2.16)</td>
<td>1.54 (1.13 to 2.12)</td>
<td></td>
</tr>
<tr>
<td>Insulin</td>
<td>Direct effect</td>
<td>1.64 (1.31 to 2.06)</td>
<td>1.62 (1.28 to 2.03)</td>
<td>1.60 (1.27 to 2.00)</td>
<td>1.60 (1.27 to 2.03)</td>
<td>1.59 (1.27 to 1.99)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Indirect effect</td>
<td>1.04 (1.02 to 1.09)</td>
<td>1.03 (1.01 to 1.08)</td>
<td>1.02 (1.00 to 1.05)</td>
<td>1.04 (1.01 to 1.08)</td>
<td>1.03 (1.01 to 1.07)</td>
<td></td>
</tr>
<tr>
<td>Hs-CRP</td>
<td>Direct effect</td>
<td>1.69 (1.34 to 2.12)</td>
<td>1.67 (1.33 to 2.11)</td>
<td>1.63 (1.09 to 2.05)</td>
<td>1.66 (1.31 to 2.10)</td>
<td>1.47 (1.15 to 1.87)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Indirect effect</td>
<td>1.05 (1.01 to 1.10)</td>
<td>1.04 (1.00 to 1.09)</td>
<td>1.02 (0.99 to 1.07)</td>
<td>1.04 (1.00 to 1.09)</td>
<td>1.02 (0.99 to 1.07)</td>
<td></td>
</tr>
</tbody>
</table>

Model 1: adjusted for age (per 1 year), sex, and parental history for diabetes.
Model 2: model 1+ hypertension.
Model 3: model 1+ overweight.
Model 4: model 1+ lipid-lowering treatment.
Model 5: model 1+ low levels of high-density lipoprotein cholesterol (<40 mg/dL for males, <50 mg/dL for females).
The ORs and corresponding CIs for 1 SD increases in naturally log-transformed apoC-III or apoC-III were calculated using the logistic regression model.

*The indirect effect indicated the effect of apoC-III on new-onset diabetes through mediators, and the direct effect referred to the effect of apoC-III on new-onset diabetes after excluding the indirect effect.
apoC-III, apolipoprotein C-III; hs-CRP, high-sensitivity C reactive protein; T2DM, type 2 diabetes mellitus.
homoeostasis and an unfavourable lipid profile only in non-diabetic males, whereas no significant associations were observed in females. Nevertheless, the exact mechanisms in females are not fully understood, and need to be addressed by further studies.

This study has several possible limitations that should be pointed out. First, information on some potential confounding factors, such as 2-hour oral glucose tolerance or haemoglobin A1c, were unavailable. However, after excluding participants with IFG, the association between apoCs and T2DM did not change. Second, although reasonably large, the sample size prevented a more detailed classification of participants and identification of possible mediators in subgroup analyses. Third, we did not measure apoC-III levels in specific lipoprotein subclasses and specifically in high-density lipoprotein; thus, we could not investigate the association between T2DM risk and apoC-III defined high-density lipoprotein particle. Finally, some significant differences were found between the eligible participants and participants unavailable for re-examination in this study. Participants who were unavailable for re-examination were more likely to be older, males, have higher levels of hs-CRP and have higher proportions of parental history of diabetes and hypertension than eligible participants. Exclusion of these individuals may lead to an underestimation of the results of this study, as a stronger relationship between apoC-III level and risk of diabetes was found among males and those age ≥60 years shown in the subgroup analyses in this study.

In conclusion, our study demonstrated that apoC-III was independently associated with a 5-year risk of new-onset T2DM in the Chinese population. In addition, triglyceride plays a crucial role in mediating the relationship between apoC-III and new-onset T2DM. Our finding should be further verified by other large prospective studies, and may inform the next direction and novel target for T2DM treatment and prevention.

Acknowledgements We gratefully acknowledge the contribution of all the investigators from participating centres in the CMCS study for data collection.

Contributors YQ, JInL and DZ contributed to initial concepts and study design. JiaL and YQ analyzed data and drafted the manuscript. All authors contributed to the acquisition or interpretation of data. MW, YL and JuL contributed to data collection. Investigators from participating centres in the CMCS study for data collection.

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval The study was approved by the Ethics Committee of Beijing An Zhen Hospital, Capital Medical University (the ethical approval number: ks2019029).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No data are available.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs Dong Zhao http://orcid.org/0000-0002-3239-3449 Yan Li http://orcid.org/0000-0003-1032-2292 Yue Qi http://orcid.org/0000-0002-6709-7041

REFERENCES


